Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity.
Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide. We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma.
Giovanis
Petros
P
Operative Unit of Medical Oncology, City Hospital of Belluno, Belluno, Italy. petros.giovanis@ulss.belluno.it
Garna
Antonella
A
Marcante
Marilisa
M
Nardi
Katiuscia
K
Giusto
Mauro
M
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects*; D008751:Methylene Blue / Q000627:therapeutic use*; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D012509:Sarcoma / Q000188:drug therapy / Q000503:physiopathology
D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D008751:Methylene Blue; D007069:Ifosfamide